Type I interferons as vaccine adjuvants against infectious diseases and cancer.
about
Improving Adoptive T Cell Therapy: The Particular Role of T Cell Costimulation, Cytokines, and Post-Transfer VaccinationRole of innate signalling pathways in the immunogenicity of alphaviral replicon-based vaccinesPorcine neonatal blood dendritic cells, but not monocytes, are more responsive to TLRs stimulation than their adult counterparts.Innate endogenous adjuvants prime to desirable immune responses via mucosal routesOral-nasopharyngeal dendritic cells mediate T cell-independent IgA class switching on B-1 B cells.Age-Associated Failure To Adjust Type I IFN Receptor Signaling Thresholds after T Cell ActivationImidazoquinoline Toll-like receptor 8 agonists activate human newborn monocytes and dendritic cells through adenosine-refractory and caspase-1-dependent pathways.IFN-beta improves BCG immunogenicity by acting on DC maturation.Peptide-based vaccines for cancer: realizing their potential.Developmental biology of the innate immune response: implications for neonatal and infant vaccine development.IFN-α as a vaccine adjuvant: recent insights into the mechanisms and perspectives for its clinical use.Initial afferent lymphatic vessels controlling outbound leukocyte traffic from skin to lymph nodes.Type I interferons as regulators of human antigen presenting cell functions.Innate Control of Adaptive Immunity: Beyond the Three-Signal Paradigm.Optimization of Fermentation Conditions for Recombinant Human Interferon Beta Production by Escherichia coli Using the Response Surface MethodologyToward self-adjuvanting subunit vaccines: model peptide and protein antigens incorporating covalently bound toll-like receptor-7 agonistic imidazoquinolines.Enhancement of anti-Aspergillus T helper type 1 response by interferon-β-conditioned dendritic cells.Prime-boost vaccinations using recombinant flavivirus replicon and vaccinia virus vaccines: an ELISPOT analysis.
P2860
Q28068378-1D68027F-B36A-4558-9D08-5B769D954180Q34573907-2A7F5263-1A51-4097-9D15-4FFAE78231ECQ34716772-DFFAAAFD-D9E6-4C10-9D31-A5EB78341242Q35143128-7BE2C109-FDE7-4A46-9B9C-36BC69DD9CBBQ35241760-5BB2AB9C-0F38-4DAE-9A6E-028AFD708633Q35864559-F03C3481-F8D1-4EE2-82A8-C82688E39B56Q36069620-B7787EC5-F0D2-430A-9785-9E3B1A4525CAQ37283820-AC325E94-87F1-4536-9D03-12D81CDDC9BAQ37340462-063FDB7A-EB08-4C04-A756-9B6F91B5775CQ37482390-D050933C-72C9-4733-85BA-69DFA66D4C43Q37867104-23C66C75-312B-41A7-B282-CE62E1227D3EQ38173858-9E81E080-7058-4034-97E7-336F7A500CCBQ38215320-13572CC1-64E1-4A4B-B151-08B7A5267E24Q39292313-4A843815-8566-437F-B4D6-1DF4BD7C67FEQ41442598-E5420467-C288-41F7-8C00-9ECA9143B1EDQ42021841-094A9ED2-389B-4B2B-A36E-D08D789E2696Q42662541-7C00B277-7EBE-4E82-81C1-295A82D66B72Q42998966-F33732B2-2B48-401D-A463-3477F9C3EEC9
P2860
Type I interferons as vaccine adjuvants against infectious diseases and cancer.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on April 2008
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Type I interferons as vaccine adjuvants against infectious diseases and cancer.
@en
Type I interferons as vaccine adjuvants against infectious diseases and cancer.
@nl
type
label
Type I interferons as vaccine adjuvants against infectious diseases and cancer.
@en
Type I interferons as vaccine adjuvants against infectious diseases and cancer.
@nl
prefLabel
Type I interferons as vaccine adjuvants against infectious diseases and cancer.
@en
Type I interferons as vaccine adjuvants against infectious diseases and cancer.
@nl
P2093
P2860
P356
P1476
Type I interferons as vaccine adjuvants against infectious diseases and cancer.
@en
P2093
Enrico Proietti
Filippo Belardelli
Laura Bracci
Valentina La Sorsa
P2860
P304
P356
10.1586/14760584.7.3.373
P577
2008-04-01T00:00:00Z